The Latest Cardiac and Vascular News
SALT LAKE CITY–(BUSINESS WIRE)–Alucent Biomedical Inc. today announced that the U.S. Food & Drug Administration granted an Investigational Device Exemption (IDE) for a U.S. clinical study of AlucentNVS, a unique light-activated, drug-coated balloon catheter technology. “AlucentNVS technology is poised to change the standard of care in treating patients undergoing life- and […]
Multicenter ACTIVATE II Study to Enroll up to 50 Patients in Australia SALT LAKE CITY–(BUSINESS WIRE)–Alucent Biomedical Inc. announced that it has enrolled the first patient in ACTIVATE II, an Australia-based First-in-Human clinical trial to evaluate the safety and efficacy of its revolutionary Natural Vascular Scaffolding (AlucentNVS) technology. The therapy is […]
SALT LAKE CITY–(BUSINESS WIRE)–Alucent Biomedical, a privately held medical technology company founded to transform the way vascular disease is treated, today announced Venita Chandra, M.D., will join the company’s scientific advisory board. Dr. Chandra is board certified in both general and vascular surgery. She is a clinical associate professor of surgery […]
Funding Will Support Clinical Trials to Evaluate the Company’s Novel Treatment for Peripheral Artery Disease SALT LAKE CITY–(BUSINESS WIRE)–Alucent Biomedical, a privately held medical technology company founded to transform the way vascular disease is treated, today announced the close of a $35 million Series B financing round led by a […]
SALT LAKE CITY–(BUSINESS WIRE)–Alucent Biomedical Inc. has received U.S. Food and Drug Administration approval to proceed with a Phase 1 clinical trial to evaluate the safety and efficacy of its revolutionary Natural Vascular Scaffolding (NVS) technology. The therapy is designed to treat peripheral artery disease (PAD) of the lower extremities, a […]
SALT LAKE CITY–(BUSINESS WIRE)–Alucent Biomedical, a privately held biotechnology company founded to transform the way vascular disease is treated, today announced the formation of its scientific advisory board with seven key appointments: Gary Ansel, M.D.; Elazar Edelman, M.D., Ph.D.; William Gray, M.D.; Larry Kraiss, M.D.; Krishna Rocha-Singh, M.D.; William Sessa, Ph.D. and Craig […]
